ALNYLAM PHARMACEUTICALS, INC.

ALNY · Nasdaq · SIC 2834: Pharmaceutical Preparations · Market Cap: $41.3B · 2,500 employees
213
SEC Filings
$237.1
Close 2026-08-28
2
Transcripts
2,500
Employees

Business Summary

Alnylam Pharmaceuticals is a global commercial-stage biopharmaceutical company pioneering RNAi therapeutics—medicines based on RNA interference that silence disease-causing genes. The company has six approved products: AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran), Leqvio (inclisiran, commercialized by Novartis), and Qfitlia (fitusiran, commercialized by Sanofi). Alnylam targets rare and prevalent diseases using GalNAc conjugate and lipid nanoparticle delivery technologies, with more than 20 active clinical programs.

Latest Stock Quote

ALNY 2026-08-28 $237.1 O:$224.465 H:$239.08 L:$223.61 Vol:1.8M VWAP:$234.8223
origin leaf: null

Next Earnings

Q2 FY2026 — expected 2026-09-20

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionALNYdiscussed Artificial IntelligenceQ3 FY2025
topic_mentionALNYdiscussed Blockchain & CryptoQ3 FY2025
topic_mentionALNYdiscussed Supply ChainQ3 FY2025
topic_mentionALNYdiscussed RegulationQ3 FY2025
topic_mentionALNYdiscussed Sovereign & GovernmentQ3 FY2025
topic_mentionALNYdiscussed AutomotiveQ3 FY2025
topic_mentionALNYdiscussed Healthcare & BioQ3 FY2025
guidanceALNYguided guidance are non - GAAP financial measures that exclud e from the corresponding GAAP measures stock - based compensation expense estimated at $345M - $375M in both the Prior FY 2025 Guidance and Q3 FY2025
guidanceALNYguided Guidance • Total TTR Net Product Revenues (PN & CM) (AMVUTTRA, ONPATTRO) $2,175 to $2,275 millionQ3 FY2025
guidanceALNYguided Guidance Non - GAAP Combined R&D and SG&A Expenses 3 $2,100 to $2,200 millionQ3 FY2025
guidanceALNYguided FY 2025 Guidance and the Updated FY 2025 Guidance Item Total Net Product Revenues 1 $2,650 to $2,800 millionQ3 FY2025
topic_mentionALNYdiscussed Supply ChainQ4 FY2024
topic_mentionALNYdiscussed RegulationQ4 FY2024
topic_mentionALNYdiscussed Sovereign & GovernmentQ4 FY2024
topic_mentionALNYdiscussed AutomotiveQ4 FY2024
topic_mentionALNYdiscussed Healthcare & BioQ4 FY2024
topic_mentionALNYdiscussed Platform & EcosystemQ4 FY2024
guidanceALNYguided Guidance 12 Disrupting an Expanding Growth Market 1 Information based on Alnylam modeling data Significant Unmet Patient Need ~80% ATTR - CM patients undiagnosed globally 1 RAPID KNOCKDOWNQ4 FY2024

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-02-122025-12-310001628280-26-007497EDGAR108K words
2025-02-132024-12-310001178670-25-000026EDGAR103K words
2024-02-152023-12-310001178670-24-000008EDGAR106K words
2023-02-232022-12-310001178670-23-000005EDGAR112K words
2022-02-102021-12-310001178670-22-000013EDGAR—
2021-02-112020-12-310001178670-21-000010EDGAR—
2020-02-132019-12-310001178670-20-000004EDGAR—
2019-02-142018-12-310001564590-19-003022EDGAR—
2018-02-152017-12-310001564590-18-002152EDGAR—
2017-02-152016-12-310001564590-17-001649EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2026-07-302026-06-300001178670-26-000062EDGAR63K words
2026-04-302026-03-310001628280-26-028605EDGAR61K words
2025-10-302025-09-300001628280-25-047345EDGAR62K words
2025-07-312025-06-300001178670-25-000090EDGAR57K words
2025-05-012025-03-310001178670-25-000052EDGAR54K words
2024-10-312024-09-300001178670-24-000053EDGAR59K words
2024-08-012024-06-300001178670-24-000041EDGAR58K words
2024-05-022024-03-310001178670-24-000023EDGAR56K words
2023-11-022023-09-300001178670-23-000023EDGAR65K words
2023-08-032023-06-300001178670-23-000015EDGAR63K words
2023-05-042023-03-310001178670-23-000011EDGAR60K words
2022-10-272022-09-300001178670-22-000026EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-07-300001178670-26-000060EDGAR8K words
2026-05-270001628280-26-038499EDGAR1K words
2026-04-300001628280-26-028601EDGAR8K words
2026-03-040001628280-26-014728EDGAR1K words
2026-02-120001628280-26-007491EDGAR9K words
2026-01-120001628280-26-001755EDGAR2K words
2025-12-110001193125-25-315047EDGAR1K words
2025-12-030001628280-25-055084EDGAR1K words
2025-10-300001628280-25-047342EDGAR8K words
2025-10-030001193125-25-230201EDGAR112K words

213 total filings indexed. 181 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Earnings Transcripts

Call DateQuarterTitle
—Q3 FY2025ALNY Q3 FY2025 Earnings Call Transcript
—Q4 FY2024ALNY Q4 FY2024 Earnings Call Transcript

Access full transcripts via API (JSON) — includes speakers, key metrics, competitive mentions, and origin provenance chain.

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACIU — AC Immune SA ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA

Tags

rare-genetic-diseases cardiovascular-diseases neurological-diseases hematology hypertension ophthalmology rna-interference-(rnai) n-acetylgalactosamine-(galnac)-conjugate-delivery lipid-nanoparticle-(lnp)-delivery hexadecyl-(c16)-lipophilic-ligand-conjugate-for-cns-and-ocular-delivery

Company Identity

CIK0001178670
TickerALNY
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
Websitehttps://www.alnylam.com
Listed2004-05-28

Get More Data

This is a static snapshot. For live, structured JSON with cryptographic provenance chain:

MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp

JSON Profile Stock Quote Origin Record
Origin Provenance
page leaf: 23a76566cb6c2104c3211c25d52605372a4128efbe7e9e66f73a3a4d1551cb1e
parent: 40254c74c50a510be20f6496ba4d13c3db87ff8aeb1862c8e8c240c47cbe4157
content hash: 73bbd00f521bf23f4cfecd0066f435ae1ebbc0c8f2c8248f1fee3a6f844edc38
signed: 2026-09-29T12:00:16.634Z
sources: 24 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf

Try it — paste this into your AI:

Look up ALNY using the MCP server at origin.rootz.global/mcp. What do their latest SEC filings show?

Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.

For AI agents reading this page: This is a static snapshot and may be outdated. For live data on ALNY, use the Origin MCP server or REST API.
MCP install: claude mcp add origin --transport http https://origin.rootz.global/mcp
API: GET https://origin.rootz.global/api/company/ALNY (~200 tokens, structured JSON with cryptographic provenance)
Tools: origin_company, origin_profile, origin_timeline, origin_filings, origin_quote, origin_transcripts, origin_search, origin_person, origin_skill
Discovery: /.well-known/ai | /llms.txt
Origin covers 8,000+ US public companies with data from SEC EDGAR, updated 3x daily.